Companies › Hansoh BioMedical R&D Company
9 active drug programs in 25 registered trials: 15 Phase 1, 7 Phase 2, 3 Phase 3; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HS-20093 anti-B7-H3 antibody-drug conjugate | B7H3, CD276 | Phase 3 | Osteosarcoma; Small Cell Lung Cancer; Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| HS-20089 Anti-B7-H4 antibody-drug conjugate with topoisomerase I inhibitor payload | B7H4 | Phase 3 | Ovarian Cancer; Advanced Solid Tumors | Mar 2027 |
| HS-20117-2 Injection EGFR-MET bispecific antibody | EGFR, MET | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer; Solid Tumors; Advanced Solid Tumors | Dec 2026 |
| HS-20137 | – | Phase 2 | Moderate-to-severe Plaque Psoriasis | Mar 2027 |
| HS-20110 | – | Phase 1 | Solid Tumors; CRC | Dec 2026 |
| HS-20124 anti-CDH6 antibody-drug conjugate (DAR-8) | CDH6 | Phase 1 | Solid Cancer | Dec 2026 |
| HRS-5041 Androgen receptor PROTAC degrader | AR | Phase 1 | Advanced Prostate Cancer | Dec 2027 |
| HS-20122 | – | Phase 1 | Advanced Solid Tumors; Lung Cancer | Jan 2028 |
| HS-20108 | – | Phase 1 | Advanced Solid Tumor | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06935409 | HS-20093 | Phase 3 | Osteosarcoma | Oncology | Jun 2026 |
| NCT07186452 | HS-20093 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2026 |
| NCT06498479 | HS-20093 | Phase 3 | Small Cell Lung Cancer | Oncology | Aug 2026 |
| NCT06621563 | HS-20117-2 Injection | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT06112704 | HS-20093 | Phase 2 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07462923 | HS-20093 | Phase 1 | Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | Oncology | Dec 2026 |
| NCT06825624 | HS-20093 | Phase 1 | Metastatic Colorectal Cancer (CRC) | Oncology | Dec 2026 |
| NCT06763159 | HS-20124 | Phase 1 | Solid Cancer | Oncology | Dec 2026 |
| NCT06892379 | HS-20110 | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT07879885 | HS-20137 | Phase 2 | Moderate-to-severe Plaque Psoriasis | Immunology | Mar 2027 |
| NCT06855069 | HS-20089 | Phase 3 | Ovarian Cancer | Oncology | Mar 2027 |
| NCT06007729 | HS-20093 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2027 |
| NCT07115446 | HS-20093 | Phase 1 | Advanced Prostate Cancer | Oncology | Dec 2027 |
| NCT07115446 | HRS-5041 | Phase 1 | Advanced Prostate Cancer | Oncology | Dec 2027 |
| NCT07775703 | HS-20117-2 Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2027 |
| NCT05830123 | HS-20093 | Phase 2 | Osteosarcoma | Oncology | Dec 2027 |
| NCT06014190 | HS-20089 | Phase 2 | Ovarian Cancer | Oncology | Dec 2027 |
| NCT06927570 | HS-20122 | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2028 |
| NCT07824882 | HS-20093 | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Mar 2028 |
| NCT06336707 | HS-20089 | Phase 1 | Advanced Solid Tumors | Oncology | Apr 2028 |
| NCT06332170 | HS-20093 | Phase 1 | Advanced Solid Tumor | Oncology | May 2028 |
| NCT06936735 | HS-20108 | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2028 |
| NCT07645222 | HS-20122 | Phase 1 | Lung Cancer | Oncology | Oct 2028 |
| NCT07283367 | HS-20110 | Phase 1 | CRC | Oncology | Dec 2029 |
| NCT06417008 | HS-20117-2 Injection | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | Oncology | Jun 2030 |
Pierre Fabre Medicament Avistone Biotechnology Shanghai JMT-Bio CSPC Megalith Biopharmaceutical Abbisko Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.